Theodore W. Laetsch, MD, an attending physician at the Cancer Center at Children’s Hospital of Philadelphia, discusses the efficacy of larotrectinib in patients with TRK-fusion cancers.
Theodore W. Laetsch, MD, an attending physician at the Cancer Center at Children’s Hospital of Philadelphia, discusses the efficacy of larotrectinib (Vitrakvi) in patients with TRK-fusion cancers.
Although efficacy data is still being collected, so far, it has been very consistent, according to Laetsch. The agent has demonstrated between a 75% to 80% response rate, with responses found to be durable. In pediatric patients, the median duration of response has not been reached.
Laetsch added that efficacy has been independent of age and histology.
0:08 | We continue to update the data on the efficacy of larotrectinib, but it's been very consistent. Between 75% and 80% of patients treated with larotrectinib who have TRK-fusion cancers have objective responses. And those responses are quite durable. In pediatric patients, I'm a pediatric oncologist, the median duration of response still hasn't been reached. The majority of patients are still ongoing on therapy. So I think the really exciting nature of the larotrectinib efficacy that we've seen is that it's both age agnostic, so there was children and adults included in the trials from very early on, and also histology agnostic, meaning that we see an activity across a very large number of different tumor types with TRK gene fusions in a very profound and durable way.